April 13, 2017
Neurocrine CEO Kevin Gorman says the company learned to run lean for years after having to deal with major setbacks and layoffs. Now, the company increased its staff from about 110 in 2016 to about 375 this month as it prepares for commercialization of its recently approved drug Ingrezza.
Stories this photo appears in:
PHARMA: FDA OK Is Sweet After Near-Death Experience
The weekend of April 7 was a tense one at the headquarters of Neurocrine Biosciences Inc., where over 300 employees collectively held their breath awaiting word from regulators. A decade-long project was about to make or break the company.